Prana raises $5m from institutional investors
Monday, 08 September, 2003
Joining the list of companies taking advantage of increased investor interest in the biotechnology sector, Prana Biotechnology (ASX:PBT) has raised AUD$5 million in a placement to institutional and sophisticated investors at a price of $0.70 per share.
According to CEO Geoffrey Kempler, the placement demonstrates a vote of confidence in the company by investors, and increased understanding of what Prana is trying to achieve.
The funds raised will be used to accelerate the pre-clinical development of the company's lead compound PBT-2 as a therapeutic for Alzheimer's disease. The drug was recently selected from a library of around 300 metal protein attenuating compounds (MPACs) to advance through to clinical trials, and in pre-clinical studies has outperformed PBT-1 (clioquinol), an existing off-label drug that has been successfully tested in proof-of-concept human studies.
"If all goes well, we would like to see Phase I trials start before the end of 2004, probably in the third quarter," said Kempler.
With existing cash, he said, the company had more than $7 million in the bank, enough for at least the next 18 months. Prana also has a milestone-based agreement in place with pharmaceutical company Schering, which will provide $7.3 million in R&D funding plus milestone payments and potentially royalties over the next few years towards new research targets identified by Prana and the development of diagnostics for Alzheimer's disease.
Algae unlocks a more ethical way to grow cells
Researchers have combined a new type of Queensland algae, Chlorella sp. BDH-1, with...
Oral drug shows promise for treating Barth syndrome
An oral drug called MA-5 can improve both heart and muscle problems in Barth syndrome, a rare...
New route into cells found for gene therapy viruses
Scientists have identified a previously unknown gateway into human cells — a receptor...